NEW YORK (GenomeWeb) – NanoString Technologies has filed a shelf registration to offer up to $100 million in common stock, preferred stock, depositary shares, debt securities, warrants, or units.

In a preliminary filing with the US Securities and Exchange Commission yesterday, the firm said that it may from time to time offer these securities — either alone or in combination — with the net proceeds supporting general corporate activities, including working capital, capital expenditures, and acquisitions of complementary products, technologies, or other businesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.